|
Apr 30
|
INOVIO to Present at Upcoming Scientific and Investor Conferences
|
|
Apr 29
|
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025
|
|
Mar 13
|
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
|
|
Mar 12
|
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
|
|
Feb 12
|
Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher
|
|
Feb 12
|
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
|
|
Feb 10
|
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
|
|
Oct 9
|
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?
|
|
Oct 1
|
INOVIO to Present at Upcoming Scientific Conferences
|
|
Jul 25
|
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107
|
|
Jul 25
|
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
|
|
May 14
|
Inovio Pharmaceuticals Inc (INO) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 14
|
Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript
|
|
May 13
|
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
May 5
|
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
|
|
May 1
|
INOVIO Reports Inducement Grants Under Inducement Plan
|
|
Apr 29
|
INOVIO to Participate in Upcoming Investor Conferences in May
|
|
Apr 29
|
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
|
|
Apr 15
|
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
|
|
Mar 26
|
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
|